Article

You have full text access to this OnlineOpen article

Mcl-1–Bim complexes accommodate surprising point mutations via minor structural changes

  1. Emiko Fire,
  2. Stefano V. Gullá,
  3. Robert A. Grant,
  4. Amy E. Keating*

Article first published online: 11 JAN 2010

DOI: 10.1002/pro.329

Issue

Protein Science

Protein Science

Volume 19, Issue 3, pages 507–519, March 2010

Additional Information

How to Cite

Fire, E., Gullá, S. V., Grant, R. A. and Keating, A. E. (2010), Mcl-1–Bim complexes accommodate surprising point mutations via minor structural changes. Protein Science, 19: 507–519. doi: 10.1002/pro.329

Author Information

  1. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

*Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 68-622, Cambridge, MA 02139

Publication History

  1. Issue published online: 22 FEB 2010
  2. Article first published online: 11 JAN 2010
  3. Accepted manuscript online: 11 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 15 DEC 2009
  5. Manuscript Revised: 11 DEC 2009
  6. Manuscript Received: 27 OCT 2009

Funded by

  • NIH. Grant Numbers: GM084181, P50-GM068762

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (681K)

References

  • 1
    Borner C ( 2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39: 615–647.
  • 2
    Lomonosova E, Chinnadurai G ( 2008) BH3-only proteins in apoptosis and beyond: an overview. Oncogene 27( Suppl 1): S2–S19.
  • 3
    Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ ( 2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183–192.
  • 4
    Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC ( 2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294–1305.
  • 5
    Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW ( 1997) Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983–986.
  • 6
    Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, Colman PM ( 2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 104: 6217–6222.
  • 7
    Smits C, Czabotar PE, Hinds MG, Day CL ( 2008) Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure 16: 818–829.
  • 8
    Denisov AY, Chen G, Sprules T, Moldoveanu T, Beauparlant P, Gehring K ( 2006) Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Biochemistry 45: 2250–2256.
  • 9
    Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW ( 2001) Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 98: 3012–3017.
  • 10
    Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD ( 2005) BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525–535.
  • 11
    Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, Swift K, Matayoshi ED, Zhang H, Thompson CB, Fesik SW ( 2000) Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci 9: 2528–2534.
  • 12
    Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC ( 2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393–403.
  • 13
    Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A ( 2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351–365.
  • 14
    Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A ( 2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171–185.
  • 15
    Yang-Yen HF ( 2006) Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci 13: 201–204.
  • 16
    Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG ( 2005) Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 280: 4738–4744.
  • 17
    Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW ( 1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90: 3516–3520.
  • 18
    Hanahan D, Weinberg RA ( 2000) The hallmarks of cancer. Cell 100: 57–70.
  • 19
    Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH ( 2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.
  • 20
    Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW ( 2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421–3428.
  • 21
    Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M ( 2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375–388.
  • 22
    van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC ( 2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389–399.
  • 23
    Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, Puthalakath H, Bouillet P, Colman PM, Huang DC, Fairlie WD ( 2008) A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 180: 341–355.
  • 24
    Boersma MD, Sadowsky JD, Tomita YA, Gellman SH ( 2008) Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain. Protein Sci 17: 1232–1240.
  • 25
    Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD ( 2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711–1713.
  • 26
    Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG ( 2008) Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 380: 958–971.
  • 27
    Lee EF, Czabotar PE, Yang H, Sleebs BE, Lessene G, Colman PM, Smith BJ, Fairlie WD ( 2009) Conformational changes in BCL-2 pro-survival proteins determine their capacity to bind ligands. J Biol Chem 284: 30508–30517.
  • 28
    Lee EF, Sadowsky JD, Smith BJ, Czabotar PE, Peterson-Kaufman KJ, Colman PM, Gellman SH, Fairlie WD ( 2009) High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL. Angew Chem Int Ed Engl 48: 4318–4322.
  • 29
    Feng W, Huang S, Wu H, Zhang M ( 2007) Molecular basis of Bcl-xL's target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of Beclin-1. J Mol Biol 372: 223–235.
  • 30
    Oberstein A, Jeffrey PD, Shi Y ( 2007) Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem 282: 13123–13132.
  • 31
    Liu X, Dai S, Zhu Y, Marrack P, Kappler JW ( 2003) The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19: 341–352.
  • 32
    Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW ( 1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381: 335–341.
  • 33
    Fu X, Apgar JR, Keating AE ( 2007) Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL. J Mol Biol 371: 1099–1117.
  • 34
    Herman MD, Nyman T, Welin M, Lehtio L, Flodin S, Tresaugues L, Kotenyova T, Flores A, Nordlund P ( 2008) Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS Lett 582: 3590–3594.
  • 35
    Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J ( 1993) Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol 229: 105–124.
  • 36
    Schneider TR, Sheldrick GM ( 2002) Substructure solution with SHELXD. Acta Crystallogr D Biol Crystallogr 58: 1772–1779.
  • 37
    de La Fortelle E, Bricogne G ( 1997) Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. Methods Enzymol 276: 472–494.
  • 38
    Emsley P, Cowtan K ( 2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
  • 39
    Murshudov GN, Vagin AA, Dodson EJ ( 1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240–255.
  • 40
    Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, III, Snoeyink J, Richardson JS, Richardson DC ( 2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375–W383.
  • 41
    Otwinowski Z, Minor W ( 1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307–326.
  • 42
    Storoni LC, McCoy AJ, Read RJ ( 2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60: 432–438.
  • 43
    Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC ( 2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948–1954.
View Full Article (HTML) Get PDF (681K)